SubsidieMeestersLassie: The first-ever painless breath analyser for people with diabetes, a breakthrough in blood glucose monitoring
Lassie breath analyser BOYDSense aims to provide painless, cost-effective, and discreet diabetes monitoring by analyzing breath VOCs for accurate glucose measurement.
Projectdetails
Introduction
Today, dogs are used to detect high and low blood glucose, cancers, and are tested for coronavirus. The new Lassie breath analyser BOYDSense will put the power of a dog’s nose into people’s hands and give them access to gentle health monitoring.
Problem Statement
Lassie starts with diabetes as it is an immense burden for 40 million people in Europe. Current glucose monitoring technologies are underused because they are:
- Highly invasive
- Expensive
- Stigmatising
- Generate a lot of waste
Solution
Lassie will transform this situation by making measurements painless, simple, discreet, and cost-effective without any consumables. By analysing Volatile Organic Compounds (VOCs) in the breath, Lassie will calculate blood glucose value within current accuracy standards.
Benefits
As a result, Lassie users will:
- Test earlier in the disease
- Test more frequently
- Achieve better diabetes management
- Experience significant cost savings
Future Outlook
EIC Accelerator will put BOYDSense on track to become a global leader in non-invasive diabetes monitoring.
Financiële details & Tijdlijn
Financiële details
| Subsidiebedrag | € 2.500.000 |
| Totale projectbegroting | € 8.710.500 |
Tijdlijn
| Startdatum | 1-8-2022 |
| Einddatum | 31-12-2025 |
| Subsidiejaar | 2022 |
Partners & Locaties
Projectpartners
- BOYDSENSEpenvoerder
Land(en)
Vergelijkbare projecten binnen EIC Accelerator
| Project | Regeling | Bedrag | Jaar | Actie |
|---|---|---|---|---|
The world’s first needle-free continuous glucose monitor to prevent and manage diabetes at scaleDeveloping a non-invasive glucose monitoring device to improve diabetes management and prevent onset for over 2 billion people through EIC blended finance support. | EIC Accelerator | € 2.500.000 | 2022 | Details |
iLoF: AI-augmented photonics to identify and quantify disease biomarkersiLoF is developing an AI-driven platform to create a personalized drug discovery tool for Alzheimer’s disease by analyzing biological samples for patient-specific signatures. | EIC Accelerator | € 2.495.850 | 2023 | Details |
The world’s first needle-free continuous glucose monitor to prevent and manage diabetes at scale
Developing a non-invasive glucose monitoring device to improve diabetes management and prevent onset for over 2 billion people through EIC blended finance support.
iLoF: AI-augmented photonics to identify and quantify disease biomarkers
iLoF is developing an AI-driven platform to create a personalized drug discovery tool for Alzheimer’s disease by analyzing biological samples for patient-specific signatures.
Vergelijkbare projecten uit andere regelingen
| Project | Regeling | Bedrag | Jaar | Actie |
|---|---|---|---|---|
Real time Liver disease early diagnosis through exhaled Volatile Organic Compounds sensingDiaNose aims to revolutionize NAFLD diagnostics with a cost-effective, hand-held device using AI to classify breath chemical signatures, achieving >90% accuracy for improved patient outcomes. | EIC Transition | € 2.499.875 | 2024 | Details |
Miniaturized plasma emission spectroscopy-based breath analysis for unobtrusive at-home monitoring and prediction of COPD exacerbationsThe Breath-Sense project aims to develop a hand-held breathalyzer for continuous at-home monitoring of COPD, enabling timely exacerbation prediction and reducing hospitalizations by up to 95%. | EIC Pathfinder | € 3.505.325 | 2023 | Details |
Metal-Organic-Framework Kinetic Array for Diabetes DetectionThis project aims to develop a novel sensor using metal-organic frameworks to selectively detect volatile organic compounds in breath for non-invasive diabetes diagnosis. | ERC Proof of... | € 150.000 | 2024 | Details |
Towards the ultimate breath analysis -based continuous healthcareVOCORDER aims to develop a compact, efficient breath analysis device using advanced laser technology and AI to provide holistic health monitoring seamlessly integrated into daily life. | EIC Pathfinder | € 3.873.437 | 2023 | Details |
Unobtrusive Continuous Multi-Metabolite Monitoring for a Physiological Care of Insulin-treated DiabetesThis project aims to revolutionize diabetes management through a fully implantable multi-metabolite monitoring system and automated insulin delivery, enhancing metabolic health and reducing complications. | EIC Pathfinder | € 3.885.462 | 2023 | Details |
Real time Liver disease early diagnosis through exhaled Volatile Organic Compounds sensing
DiaNose aims to revolutionize NAFLD diagnostics with a cost-effective, hand-held device using AI to classify breath chemical signatures, achieving >90% accuracy for improved patient outcomes.
Miniaturized plasma emission spectroscopy-based breath analysis for unobtrusive at-home monitoring and prediction of COPD exacerbations
The Breath-Sense project aims to develop a hand-held breathalyzer for continuous at-home monitoring of COPD, enabling timely exacerbation prediction and reducing hospitalizations by up to 95%.
Metal-Organic-Framework Kinetic Array for Diabetes Detection
This project aims to develop a novel sensor using metal-organic frameworks to selectively detect volatile organic compounds in breath for non-invasive diabetes diagnosis.
Towards the ultimate breath analysis -based continuous healthcare
VOCORDER aims to develop a compact, efficient breath analysis device using advanced laser technology and AI to provide holistic health monitoring seamlessly integrated into daily life.
Unobtrusive Continuous Multi-Metabolite Monitoring for a Physiological Care of Insulin-treated Diabetes
This project aims to revolutionize diabetes management through a fully implantable multi-metabolite monitoring system and automated insulin delivery, enhancing metabolic health and reducing complications.